Epidermal growth factor receptor mutational assay for patients with non small-cell lung carcinoma
Mundy L, Hiller JE
Record ID 32012000213
English
Authors' recommendations:
The mutational analysis of the epidermal growth factor receptor (EGFR) gene by polymerase chain reaction (PCR) assay is highly sensitive and specific when compared to standard DNA sequencing. Most of the studies included in this assessment have been of poor quality (level IV diagnostic evidence) and have been "hypothesis generating"; this is the same patient group with non small-cell lung carcinoma (NSCLC) have had their DNA trawled to find potential differences to explain their response to gefitinib. Gefitinib may result in an increased survival benefit in a select group of patients; however it is unclear from the literature exactly what the characteristics of this patient group should be. It is still unclear from the available published evidence whether EGFR mutations are a good prognostic marker for successful treatment of patients with gefitinib. As a result it is recommended that this technology be archived.
Details
Project Status:
Completed
Year Published:
2006
URL for published report:
Not Available
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Carcinoma, Non-Small-Cell Lung
Contact
Organisation Name:
Adelaide Health Technology Assessment
Contact Address:
School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
ahta@adelaide.edu.au
Contact Email:
ahta@adelaide.edu.au
Copyright:
Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.